# AvenCell Therapeutics

> Clinical-stage allogeneic CAR-T company that entered a financing agreement with Ligand worth up to $47 million.

## Why it is interesting

The financing is structurally unusual: up to $41M of royalty financing plus up to $6M of Series C equity, not a plain $47M venture round.

## Profile

- **Latest funding:** Royalty financing + Series C equity — Up to $47M total ($41M royalty + $6M equity) (September 24, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** Not publicly disclosed
- **Stage:** growth
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-09-30
- **Latest funding investors:** Ligand Pharmaceuticals

## Key facts

- Sep 24, 2026: up to $47M financing agreement
- Up to $41M is royalty financing; up to $6M is Series C equity

## Funding history

- Royalty financing + Series C equity · Up to $47M total ($41M royalty + $6M equity) · September 24, 2026
  Source: https://www.sec.gov/Archives/edgar/data/886163/000088616326000054/lgnd_avencellreleasex20260.htm

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** September 30, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/avencell-therapeutics